| [1] | McMurray JJ, Pfeffer MA. Heart failure[J].Lancet,2005,365: 1877-1889. |
| [2] | Braunwald.Braunwald’s heart disease[M]. 9th ed,USA:Saunders,2011:459-651. |
| [3] | Allen LA, O'Connor CM. Management of acute decompensated heart failure[J].CMAJ,2007, 176(6): 797-805. |
| [4] | Kapoor JR, Perazella MA.Diagnostic and therapeutic approach to acute decompensated heart failure[J].Am J Med, 2007, 120(2):121-127. |
| [5] | 中华医学会心血管病学分会,中华心血管杂志编辑委员会.急性心力衰竭诊断和治疗指南[J].中华心血管病杂志,2010,38(3):195-208. |
| [6] | 元 鹏 张朝香.ACC/AHA2009 成人心力衰竭诊断与治疗最新指南简介(二)[J].中华保健医学杂志,2010,12(5):403-406. |
| [7] | Grossini E, Molinari C, Caimmi PP,et al.Levosimendan induces NO production through p38 MAPK,ERK and Akt in porcine coronary endothelial cells:role for mitochondrialK(ATP)channel[J].Br J Pharmacol, 2009,156(2):250-261. |
| [8] | Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent[J].Anesthesiology, 2006, 104( 10): 556- 569. |
| [9] | Alexandre M, Markku S. N, Milton P, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure the SURVIVE randomized trial[J].JAMA, 2007, 297 (17):1883-1891. |
| [10] | McMurray JJ, Adamopoulos S, Anker SD,et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012[J].Eur J Heart Fail, 2012,14(8):803-869. |
| [11] | Follath F.N treatments for decompensated heart failure: focus on levosimendan drug[J].Des Devel Ther,2009,3: 73-78. |
| [12] | Silva-Cardoso J,Ferreira J,Oliveira-Soares A, et al.Effectiveness and safety of levosimendan in clinical practice[J].Rev Port Cardiol, 2009,28 ( 2 ):143-154. |